Skip to main content
. Author manuscript; available in PMC: 2021 Aug 19.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2014 Aug 4;90(2):369–375. doi: 10.1016/j.ijrobp.2014.05.034

Table 3.

Early treatment response as determined by gadolinium-enhanced MRI 1 month after treatment and 6-month PFS and median OS

Response All patients rGBM rAA Median PFS (mo) Median OS (mo)
Partial response 1 (10%) 1 (14%) 0 (0%) 21.8 27.5
Stable disease 6 (60%) 4 (57%) 2 (66%) 9.5 13.7
Progressive disease 3 (30%) 2 (29%) 1 (33%) 2.5 6.3
6-month PFS 5 (45%) 4 (50%) 1 (33%)
Median OS (mo) 11.0 12.7 11.0

Abbreviations: MRI = magnetic resonance imaging; OS = overall survival; PFS = progression-free survival; rAA = recurrent anaplastic astrocytoma; rGBM = recurrent glioblastoma multiforme